key: cord-0799415-4znqc7dr
authors: Yang, Xiao; Li, Zhifeng; Wang, Binbin; Pan, Yunbao; Jiang, Chaoyun; Zhang, Xingguo; Yang, Yadong; Zhou, Chenliang; Hu, Chang; Zhang, Zhijiang; Xu, Haibo; Liao, Weijin; Vizcaychipi, Marcela P.; Sanders, Robert D.; Li, Yirong; Ma, Daqing; Peng, Zhiyong
title: Prognosis and antibody profiles in survivors of critical illness from COVID-19: a prospective, multi-centre, cohort study
date: 2021-11-26
journal: Br J Anaesth
DOI: 10.1016/j.bja.2021.11.024
sha: aa6c3912dc96904f2da22187d6fa1fc638afa8ff
doc_id: 799415
cord_uid: 4znqc7dr

BACKGROUND: There is a need to assess the long-term outcomes of survivors from critically ill COVID-19. METHODS: Ninety-two critically ill survivors of COVID-19 from four hospitals in Hubei province, China participated in this prospective cohort study. Multiple characteristics including lung function (lung volumes, diffusing capacity of lung for carbon monoxide, chest CT scores and walking capacity), immune status (SARS-COV-2 neutralizing antibody and all sub-types of IgG against SARS-CoV-2, immune cells in response to ex-vivo antigen peptide stimuli, lymphocyte count and its sub-type), liver, coagulation and kidney function, quality of life, cognitive function and mental status were assessed after 3, 6 and 12-months of follow-up. RESULTS: Among the 92 enrolled survivors, 72 (78%) patients required mechanical ventilation. At 12 months, the predicted percentage diffusing capacity of lung for carbon monoxide was 82% (IQR, 76%-97%) with a residual volume of 77% (64%-88%). Other lung function parameters and the 6-minute walk test improved gradually over time and were almost back to normal by 12 months. The titers of IgG and neutralizing antibody to COVID-19 remained high at 12 months compared to non-COVID-19 infected controls, although IgG titers decreased significantly from 33.96 AU/ml (IQR, 23.79-74.30) to 14.98 AU/ml (5.75-24.30) (P<0.001), whilst neutralizing antibodies decreased from 29.99 AU/ml (IQR, 19.43-53.93) at 6 months, to 19.75 AU/ml (13.13-29.84) (P<0.001) at 12 months. In general liver, kidney, physical and mental function also improved over time. CONCLUSIONS: Critically ill COVID-19 survivors show some persistent long-term impairments in lung function, however the majority of these tests are normal by 12 months. These patients still have detectable levels of neutralising antibodies against SARS-COV-2 and all types of IgG at 12 months, but the levels had declined over this time period.

The long-term prognosis of survivors who were critically ill with COVID-19, remains unknown. 1, 2 Previous reports have shown there are persistent impairment in lung function, physical capacity as well as psychological sequelae following severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) pneumonia; these can last from months to years. 3, 4, 5, 6, 7 Recent studies have reported that patients with mild COVID-19 infection often have complications such as fatigue, dyspnoea, depression and reduced lung function. 8, 9, 10, 11, 12, 13, 14 In addition, the titers of antibodies against SARS-CoV-2 in critically ill patients with COVID-19 remain unknown. A six-month follow-up study of survivors of COVID-19 showed decreasing seropositivity of neutralising antibodies and IgG titers over time. 8 Another study reported a 11.7% decrease in antibody levels in more than half of the asymptomatic patients after 2-months of recovery. 15 In survivors, the memory B cell response lasted no longer than 6 months, and the memory T cell responses declined over time after SARS-CoV-2 infection. 8 Concerns about diminished immunity and the re-infection of SARS-CoV-2 are emerging, as the level and timing of the immunity against reinfection remain unknown. 16 Critically ill survivors are a cohort of patients with the most severe form of organ injuries, therefore it is important to study their long-term outcomes in terms of physiological, haematological, biochemical and humoral function.

Thus, in this study, we aimed to evaluate the dynamic changes in (1) 

We used electronic medical records to extract data including demographic information, underlying comorbidities, laboratory measurements, treatment measures and outcomes. The Acute Physiology and Chronic Health Evaluation II (APACHE II) score within the first 24 hours after admission, daily Sequential Organ Failure Assessment (SOFA) score, duration of mechanical ventilation, ICU stay and hospital stay were also recorded. 18 Lung function data are presented as the percentage of the predicted value. High-resolution computed tomography scans of the chest were evaluated by two chest radiologists using established methods. 19

The six-minute walk test was performed by respiratory therapists in the pulmonary rehabilitation centre according to published guidelines. 20 Repeats were performed at the same time of the day to minimise intra-day variability. The distances walked by the patients during the 6-minute walk test are presented as a percentage of the predicted value. 21 J o u r n a l P r e -p r o o f

The number of CD4+ and CD8+ T cells, B cells, and NK cells were determined using TruCOUNT tubes and BD Multitest 6-color TBNK Reagent Kit (BD Biosciences) according to the manufacturer's instructions. T cells subsets assay was performed as previously reported. 22 Different T cell subsets were defined as follows: costimulatory molecule (CD28+CD4+ or CD28+CD8+ T cells), activated T cells (HLA-DR+CD3+ or HLA-DR+CD8+T cells), naive/memory

To assess viral specific cellular immunity, whole blood was stimulated with recombinant antigen peptides (NP, S1, S2, and RBD) and phytohemagglutinin served as the control and followed by cytokine measurements. Six cytokines, including tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), IL-6, IL-2, IL-4 and IL-10 were determined (Autobio Diagnostic Co., Zhengzhou, China). Briefly, 25 μL serum was mixed with equal volumes of capture beads and incubated in the dark with 25 μL of Phycoerythrin-conjugated antibodies for 2.5 hours at room temperature. The beads were then centrifuged at 200 x g for 5 minutes, the supernatant was gently aspirated and resuspended in phosphate-buffered saline (100 μL) and analysed using a flow cytometer (BD Bioscience-Pharmingen).

SARS-CoV-2 antibody titers were measured at 6 and 12 months. The paramagnetic particle chemiluminescent immunoassay (CLIA) was used for the qualitative determination of 2019-nCoV neutralizing antibody, IgG, IgM and IgA in human serum and plasma using the Health-related quality of life SF-36 was used to measure health-related quality of life, which includes eight multiple-item subscales and evaluates physical function, social functioning and role limitations. Scores for each aspect range from 0 (worst) to 100 (best) with higher scores indicating better healthrelated quality of life. Mini-Mental State Examination was used to assess cognition. 23 Zung's Self-Rating Anxiety Scale and Hamilton Rating Scale for Depression were used to assess anxiety and depressive symptoms. 24

A prospective statistical analysis protocol was implemented in our study with all researchers who participated in the data collection and analyses were blinded to the patients' outcomes.

Blood samples were analysed in duplicate. Data are presented as mean and standard deviation (SD) if normally distributed, or as median with interquartile range (IQR) if not. Categorical variables are presented as frequency and percentage. Comparisons between two continuous variables with a normal distribution were undertaken using a two-tailed Student's t-test, otherwise a Mann-Whitney, Chi-square or Fisher's exact test was used wherever appropriate.

For repeated measures with a normal distribution, a two-way analysis of variance was used followed by Newman-Keuls test, otherwise a Kruskal-Wallis test was used. Multiple testing of P values were corrected for with Bonferroni corrections, with a P < 0.05 considered statistically significant. Statistical analysis was performed using statistical software (SPSS INC., Chicago, IL, USA) and figures were constructed using Origin (Version 9.6. Northampton, Massachusetts, USA) and GraphPad Prism (Version 8.0, San Diego, CA, USA).

From January 7, 2020 to March 15, 2020, 171 critically ill patients were admitted to ICUs in the four hospitals (Fig. 1) . Demographics and clinical characteristics of the 171 patients were shown in Table 1 

Overall the greatest change in lung function tests were observed in VC, FVC, FEV1 and DLCO.

At 12 months the median DLCO was still 82% (IQR, 76%-97%) of predicted value, although this value had improved compared to those of 76% (65%-88%) and 75% (64%-88%) at 3 and 6 months, respectively (P=0.015). The RV at 12 months was 77% (IQR, 64%-88%) of predicted, compared to 80% (IQR, 67%-95%) and 81% (IQR, 70%-91%) at 3 and 6 months, respectively.

The median predicted value of FVC was 91% (78%-101%), 94% (84%-103%) and 101% (89%-111%) at 3, 6 and 12 months, respectively (P=0.001). There were no significant differences in J o u r n a l P r e -p r o o f FEV1/FEV, TLC, and chest CT scores over time ( Supplementary Fig. S1 and Supplementary Fig.   S2 ).

The median distance during the six-minute walk test was 486 meters (IQR, 428-548), 526 (463-584) and 533 (464-575) at 3, 6 and 12 months, respectively (P=0.017). The median percentage of predicted values of six-minute walk test was 89% (81%-99%), 97% (88%-105%) and 99% (91%-106%) at 3, 6 and 12 months, respectively (P<0.001) ( Supplementary Fig. S1 and Supplementary Fig. S2 ).

Lung function tests were also compared between intubated and non-intubated survivors (Fig.   2 ). Almost all the parameters at 3 months in the intubated survivors were worse than those in the non-intubated survivors (P<0.01). However, these differences were largely not evident at later time points. At 12 months, TLC and RV were still significantly lower in the intubated survivors than those of the non-intubated survivors.

All these survivors were SARS-COV-2 nucleic acid amplification (NAAT) negative. The (Fig. 3) . Recombinant antigen peptide (NP, S1, S2 and RBD) ex-vivo stimulation test revealed higher levels of cytokine secretion in blood harvested at 12-months (P<0.05) relative to healthy non-infected controls ( Table 2 ). In addition, there was no significant difference in cytokine release between survivors who were seropositive for the neutralizing antibody Table S1 ). T lymphocyte function assay showed that the percentage of activated T cells (HLA-DR+CD3+/CD3+ T cells, HLA-

T cells) were far higher than the normal range while the mean percentage of CD28+CD8+/ CD8+T were relatively lower than the normal range (Supplementary Table S2 ). Table S3 ).

Patients reported feeling of short of breath after activities (54.4%) and palpitations (51.8%) at month 3, but this was significantly reduced by 6 months (38.5% and 30.8%) and 12 months We found lung function improved gradually and was almost back to the normal levels at 1 months post-ICU discharge with the exception of DLCO and RV. There was also persistent immunity against SARS-COV-2 as measured by high titers of antibodies to SARS-COV-2 (though on a decreasing trend) and active virus-specific immune cell function. Other parameters including liver, kidney physical and mental functions also appeared to improve over time.

Previous SARS survivors had impaired DLCO ranging from 15.5% to 43.6%. 4, 25, 26, 27, 28, 29 It has been reported that residual obstructions and restrictive defects as well as impaired pulmonary gas exchange can last for up to 3 years in survivors of severe ARDS . 30 A recent study demonstrated that lung function (except DLCO) following COVID-19 returned to normal within 1-year, but all these results came from non-intubated patients. 31 In our study, two-thirds of the patients were mechanically ventilated for moderate-to-severe ARDS. Overall significant impairments were present by month 3, but these continued to improve over time. As expected, there was a trend that intubated survivors had worse lung function than nonintubated survivors. Overall, the most significant changes in lung function were gas diffusive capacity and residual volume with about 20-25% of impairments at 1-year. Other measurements of lung function together with the six-minute walk test returned to near normal levels by 12 months. Chest CT scores were not significantly improved over time, although the resolution of radiographic abnormalities began to be observed by the 4 th week after admission. 32 This unchanged CT score might be explained either by an inherent limitation of the semi-quantitative CT score but also possibly by fibrotic changes in the lung. The latter is supported by the lung function data. We propose that fibrosis and subsequently impaired diffusion capacity were the main changes of the lung function in the survivors after critically ill COVID-19. Nevertheless, our patients recovered generally better than those patients previously reported. 8,10, 11, 12 This difference may be due to differing inclusion/exclusion criteria where we excluded 6 patients due to prolonged hospital stay for neurological rehabilitation and another 6 patients with prior chronic lung diseases. Another reason may be that our patients were instructed to have respiratory exercises and rehabilitation at home immediately after discharge from hospital through social media (e.g. Wechat).

In the acute phase of COVID-19, peripheral lymphocyte subset alteration has been characterised by a decreased number of CD4+ T cells, CD8+ T cells, B cells, and NK cells. 33 In our study, the absolute number of various T lymphocytes returned to the normal range at 12months after ICU discharge. The increase in the activated T cell population (HLA-

immunity. Interestingly, it was noted that all the subtypes of IgG and neutralising antibodies were maintained at high titers within one year albeit with decreasing trend. These results were different from a previous report in which these protective antibodies in the most survivors disappeared by six months. 8 However, the survivors in that study were from all severity levels of the patients, including asymptomatic, mild and severe cases. It is unknown whether the different severity of infection affected the subsequent immunity. To further evaluate the virus-specific immune cellular functions of these survivors, we used ex-vivo blood stimulus test and found that the high levels of cytokines were released upon recombinant antigen peptide (NP, S1, S2 and RBD) challenge at 1-year after ICU discharge. All these implied that the acquired immunity against SARS-COV-2 were preserved within one year in our critically ill COVID-19 patients.

Our study showed the inflammatory biomarkers, such as ferritin, CRP and ESR, were normal This study is not without limitations. First, there were no data to compare the disease severity and long-term outcomes of critically ill COVID-19 patients with survivors of ARDS of other aetiologies. Secondly, there was no baseline data available on all variables examined within our cohort of patients due to the nature of the unprecedented pandemic. Although we have excluded patients with prior history of chronic lung disease and sought to use percentages of predicted values based on the age and gender, it is still unknown how our data represents critically ill COVID-19 patients overall particularly given our relatively small sample size. Thirdly, only limited immunological cell functions were measured; in particular, T cell subset data were not available at 3-months and, therefore, a comprehensive "picture" of immune status is not known. Lastly, the proportion of patients lost to follow-up is relatively high. The main reason for this loss to follow-up was that patients were now working/living outside Hubei, nevertheless we included theeir data at the 3 month follow up when they were interviewed via telephone and all were recovering well.

In survivors of critical illness due to COVID-19, markers of lung function improved gradually during 12-months of follow-up, and was almost back to normal levels except for the gas diffusive capacity and residual volume. The acquired immunity against COVID-19 was still maintained with high titers of both of IgG and neutralizing antibody, as well as active cellular immune function. COVID-19 is a systemic disease that affects multiple organ systems and this also leads to persistent changes in quality of life. 35 Consequently, the long-term recovery of such patients needs to be closely monitored to allow the implementation of appropriate care and support .

J o u r n a l P r e -p r o o f Predicting values (%) of lung function based on age and gender are expressed as median with IQR; *P < 0.05; **P < 0.01: comparison between intubated and non-intubated survivors.

VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; Adjusted-DLCO, diffusion capacity for carbon dioxide was adjusted for age, sex and haemoglobin. 

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome

Lung Function Deficits and Symptom Burden in Survivors of COVID-19 Requiring Mechanical Ventilation

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients

Trends over Time of Lung Function and Radiological Abnormalities in COVID-19 Pneumonia: A Prospective, Observational, Cohort Study

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Standardisation of the single-breath

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study

Screening for anxiety and depression: reassessing the utility of the Zung scales

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Novel Coronavirus Disease 2019 (COVID-19) Pneumonia Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section Computed Tomography Features During Recovery

1-year pulmonary function and health status in survivors of severe acute respiratory syndrome

Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome

Exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome. Duration of hospital stay, days, medium (IQR)

Number of patients enrolled in testing

Chronic lung diseases were defined as asthma and chronic obstructive pulmonary disease. Cardiovascular diseases were defined as coronary heart disease, chronic heart failure, valvular heart disease and arrhythmia. Immunocompromised conditions were defined as human immunodeficiency virus infection, malignancy, liver cirrhosis, or chronic renal failure, or if immunosuppressive therapy was being administered

Abbreviations: HFNO, high flow nasal oxygen

CRRT, continuous renal replacement therapy; ICU, intensive care unit. Normal Range (pg/ml)

Negative control, negative stimulus; Peptide group, stimulated by SARS-Cov-2 peptides (receptor binding domain, RBD, S1, S2 and Nucleocapsid); Data were reported as median (IQR)

SF-36 score Physical function, medium (IQR) 90.6 85.00

Role emotional, medium (IQR)

Social function, medium (IQR)

Abbreviations: SF-36, Short Form-36

Data were reported as no./total (%) or median (IQR)

We would like to thank the staff from the department of Critical Care